USDA Western Human Nutrition Research Center
Davis, California, 95616, United States
NCT Number: NCT05792137
The purpose of this research is to determine the role of a type of immune cell in blood, called a non-classical monocytes (NCMs), following consumption of a high-fat meal. Previous studies have found that monocytes are important for blood vessel health. In this study, two different high-fat meals will be used to study the effect of different types of dietary fat on postprandial NCMs. The investigators will characterize NCMs in both fasting conditions and following consumption of two different high-fat meals, and will evaluate whether the type of fat in a meal affects NCMs in blood.
Looking for future studies?
Notify Me18 year–39 year
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
Monocytes are a heterogeneous population of circulating blood cells that contribute to tissue integrity as well as to innate and adaptive immune defense. There are three well-characterized subsets based on their relative expression of surface antigens, cluster of differentiation 14 (CD14) and cluster of differentiation 16 (CD16). Monocytes originate from myeloid precursors in the bone marrow and enter the circulation as classical monocytes (CLMs). CLMs represent a transient cell population with a diverse differentiation potential. CLMs comprise 80-90% of the circulating blood monocyte pool and remain in circulation for approximately one day before either migrating into tissue to repopulate the tissue resident macrophage population or maturing into non-classical monocytes (NCMs). NCMs comprise only 5-10% of the circulating blood monocyte pool but have a much longer circulating lifespan of approximately 7 days. NCMs exhibit conflicting functions as anti-inflammatory caretakers of vascular tissue and as contributors to the pathogenesis of disease.
Metabolic responses to food consumption influence the risk of cardiometabolic disease. Postprandial glycemia and lipemia modulate vascular health by altering endothelial function and inducing oxidative stress, inflammation, and apoptosis. Consumption of a single high-fat meal increases circulating interleukin 6 (IL-6), enhances expression of monocyte adhesion molecules, reduces flow-mediated dilation, and increases markers of oxidative stress in human subjects. Although NCMs are described as vascular housekeepers with distinct motility and crawling patterns allowing them to actively surveil endothelium and scavenge luminal debris, their role in the postprandial state is currently unknown.
To better understand the function of postprandial NCMs following consumption of a single high-fat mixed macronutrient challenge meal, the investigators propose a study following a crossover design in which participants will consume one of two isocaloric high-fat challenge meals spaced two-weeks apart, a high-saturated fat mixed macronutrient challenge meal or a high-monounsaturated fat mixed macronutrient challenge meal. Blood at fasting and at six hours postprandial will be collected and the proportion of NCMs and their integrin expression will be analyzed by flow cytometry while changes in global gene expression will be measured by RNA-sequencing.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
High saturated fat challenge meal made with palm oil
High mono unsaturated fat challenge meal made with olive oil
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte subsets will be analyzed using flow cytometry. Subset analysis will be performed by labeling immune cells with anti-cluster of differentiation antigen 45 (anti-CD45), cluster of differentiation antigen 91 (anti-CD91), anti-CD14, and anti-CD16 fluorescently labeled antibodies.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
White blood cell (WBC) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Lymphocyte (LY) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte (MO) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Neutrophil granulocyte (NE) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Eosinophil (EO) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Basophil (BA) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Red blood cell (RBC) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Hemoglobin (HGB) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Hematocrit (HCT) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Mean corpuscular volume (MCV) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Mean corpuscular hemoglobin (MCH) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Mean corpuscular hemoglobin concentration (MCHC) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Red blood cell distribution width (RDW) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Red blood cell distribution width standard deviation (RDW-SD) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Platelet (PLT) count will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Mean platelet volume (MPV) will be measured by a DxH 520 Hematology analyzer.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD45 fluorescently labeled antibodies.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD91 fluorescently labeled antibodies.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD14 fluorescently labeled antibodies.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Transcriptional changes in non-classical and classical monocytes will be measured by RNA-sequencing following the isolation of non-classical monocytes from peripheral blood by fluorescence-activated cell sorting (FACS) using anti-CD16 fluorescently labeled antibodies.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte adhesion molecule expression of very late antigen-4 (VLA-4) will be assessed using flow cytometry.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte adhesion molecule expression of C-X3-C motif chemokine receptor 1 (CX3CR1) will be assessed using flow cytometry.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte adhesion molecule expression of Notch2 will be assessed using flow cytometry.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte adhesion molecule expression of colony stimulating factor 1 receptor (CSFR1) will be assessed using flow cytometry.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Monocyte adhesion molecule expression of scavenger receptor class B, member 3 (CD36) will be assessed using flow cytometry.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Filamentous-actin (F-actin) intensity will be assessed using phalloidin.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Plasma markers of systemic inflammation including interleukin-6 will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Plasma markers of systemic inflammation including interleukin-8 will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Acute phase reactants including C-reactive protein (CRP) will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Acute phase reactants including serum amyloid A (SAA) will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Chemokines including chemokine ligand 2 will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Plasma markers of oxidative stress including 8-isoprostane F2alpha will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Endothelial activation including soluble cluster of differentiation antigen 146 (CD146) will be measured by ELISA.
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Lipid-related markers including triglycerides will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Lipid-related markers including total cholesterol will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Lipid-related markers including HDL-cholesterol (HDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Lipid-related markers including LDL-cholesterol (LDL-C) will be measured by auto-analyzer, Cobas Integra 400+ instrument
Time frame: Measured from samples taken at 0 hours (fasting) and 6 hours (postprandial) on 2 test days
Plasma glucose will be measured by auto-analyzer, Cobas Integra 400+ instrument
USDA, Western Human Nutrition Research Center
Fed
Western Human Nutrition Research Center (WHNRC) Postprandial Monocyte Study
Acronym: PPMS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07409480
Atrophy, Cognition Disorders
Reus, Tarragona, Spain
View Trial DetailsNCT06263686
Immune System, Inflammation
View Trial DetailsNCT07583719
Breast Cancer, Breast Diseases
View Trial DetailsNCT06513520
Immune System
Caluire-et-Cuire, France
View Trial Details